In the present study, for the first time, we have evaluated the role of EGFR family pan-inhibitors canertinib and afatinib in the inhibition of MUC4-mediated invasion, motility and metastasis of pancreatic cancer cells. The gene discussed is MUC4; the disease is familial pancreatic carcinoma.